LupinQ2 FY24

Lupin Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,950P/E: 15.8Market Cap: ₹89.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company targets steady growth aiming for $5 billion revenue in 3-5 years (Page 18).
  • US business expected to ramp up to around $250 million per quarter by FY26, driven by new product launches including Tolvaptan, Liraglutide (subject to approval), and ophthalmic injectables (Pages 15, 16).
  • Tiotropium (Spiriva) market share projected to ramp from 25% towards 35-40% within a year, with stable pricing expected (Pages 7-9).
  • India business plans to outperform the market with mid to long-term growth better than high single digits, gaining from new introductions and volume increases (Pages 11-12).
  • Strong growth expected from complex generics, injectables, inhalers, and ophthalmics, with multiple filings and launches lined up especially in FY25 and FY26 (Pages 11-14).
  • Europe and other non-US markets also showing robust sales growth and capacity expansions planned to support launches in multiple regions (Page 9).

See what Lupin management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript on page 18 and surrounding pages does not mention any current or future plans for fundraising through debt or equity. Key points related to finances include: - Net debt reduced from INR 2,527 crores in March 2023 to INR 1,806 crores as of September 30, 2023. - Gross debt reduced by INR 720 crores during this period. - No mention of new equity or debt fundraising plans. - Focus appears to be on growth through product launches and operational efficiencies rather than new capital raising. - Operating working capital has improved, indicating good management of existing resources. Therefore, no indications of planned new fundraising through debt or equity were discussed in this Q2 FY24 earnings call.

See what Lupin management said on order book — free account, 30 seconds.

Capex plans

Yes
The transcript does not explicitly detail current or future capex/capital investments or strategic investments. However, related points inferred are: - Capacity expansion has been done to support growth in the U.S. and other markets including Australia, Canada, and Europe. (Page 9) - Continued investment in R&D focused on biosimilars, injectables, complex generics, inhalers, ophthalmics, and first-to-file products. Planned R&D spend is INR 1,500 to 1,600 crores for the full year. (Pages 6, 11, 13) - Pithampur Unit 2 clearance allows launch of multiple ophthalmic complex generics in next fiscal years. (Page 11) - Focus on US complex generics portfolio ramp-up including inhalation and ophthalmic products, biosimilars (e.g., Pegfilgrastim filing update), and launch of new products like Tolvaptan in FY26. (Pages 11, 12, 15, 18) - ESG initiatives accelerated significantly over last 2 years, reflecting strategic non-capital sustainability investments. (Page 7) No explicit mention of new capital expenditure amounts or new strategic investments was provided.

Track Lupin — get its next earnings analysis in your feed

How does Lupin rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisLupin
Rev 3Mar 3

How does Lupin rank in Pharmaceuticals & Biotechnology?

Compare Lupin against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →